Biosafe enters China stem cell market after SFDA approval

Singapore: Swiss company Biosafe, which is active in the field of design, manufacture and marketing of automated cell processing systems for stem cell banking and regenerative medicine applications, has obtained Chinese SFDA registration for its Sepax device, completing its worldwide registration program.

Sepax is now available for immediate sale in China through Biosafe's recently established local subsidiary in Shanghai and is the first fully-automated cell separation system, approved for use in the Chinese stem cell processing market.

Mr Olivier Waridel, CEO, Biosafe, said that, "This is a major milestone for the Biosafe Group and we are pleased to offer our industry-leading products throughout China. We look forward to contributing to developing its rapidly expanding cord blood banking, by providing state-of-the-art technology and premium service."